Cep 1347游离态 /CEP-1347
{[allProObj[0].p_purity_real_show]}
货号：A784584
同义名：
KT7515
CEP 1347 is an inhibitor of c-jun N-terminal kinase (JNK) signaling.
CEP-1347 化学结构
CAS号：156177-65-0
CEP-1347 3D分子结构
CAS号：156177-65-0
| 规格 |
价格 |
会员价
|
库存 |
数量 |
| {[ item.pr_size ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]}
{[ getRatePrice(item.pr_rmb_sale, 1,1) ]}
|
{[ getRatePrice(item.pr_rmb, 1,1) ]}
{[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]}
|
{[ getRatePrice(item.pr_rmb, 1,1) ]} |
{[ getRatePrice(item.pr_rmb_sale, 1,1) ]}
{[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]}
{[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]}
|
现货 |
咨询
|
-
+
|
CEP-1347 质控信息
| Mulberroside A |
✔
|
|
|
|
|
{[allProObj[0].p_purity_real_show]} |
| Loureirin B |
✔
|
|
|
|
Potassium Channel,Calcium Channel
|
{[allProObj[0].p_purity_real_show]} |
| Ginsenoside Re |
✔
|
|
|
|
NF-κB
|
{[allProObj[0].p_purity_real_show]} |
| (+)-(3R,8S)-Falcarindiol |
✔
|
|
|
|
STAT,ERK
|
{[allProObj[0].p_purity_real_show]} |
| trans-Zeatin |
✔
|
|
|
|
p38 MAPK,ERK
|
{[allProObj[0].p_purity_real_show]} |
| Urolithin B |
✔
|
|
|
|
ERK,NF-κB
|
{[allProObj[0].p_purity_real_show]} |
| Cucurbitacin IIb |
✔
|
|
|
|
NF-κB
|
{[allProObj[0].p_purity_real_show]} |
| Astragaloside IV |
✔
|
|
|
|
Akt,mTOR,NF-κB
|
{[allProObj[0].p_purity_real_show]} |
| NDMC101 |
✔
|
|
|
|
|
{[allProObj[0].p_purity_real_show]} |
| DB07268 |
|
++++
|
|
|
|
{[allProObj[0].p_purity_real_show]} |
| SP600125 |
+
|
+++
|
+++
|
+++
|
|
{[allProObj[0].p_purity_real_show]} |
| JNK-IN-7 |
|
++++
|
++++
|
++++
|
|
{[allProObj[0].p_purity_real_show]} |
| JNK-IN-8 |
|
++++
|
+++
|
++++
|
|
{[allProObj[0].p_purity_real_show]} |
| 3,3',5-Triiodo-L-thyronine |
|
++
|
++
|
+++
|
|
{[allProObj[0].p_purity_real_show]} |
| IQ-1S free acid |
|
+
|
++
|
+++
|
|
{[allProObj[0].p_purity_real_show]} |
| BI-78D3 |
++
|
++
|
++
|
++
|
|
{[allProObj[0].p_purity_real_show]} |
| Bentamapimod |
|
+++
|
+++
|
++
|
|
{[allProObj[0].p_purity_real_show]} |
| Resveratrol |
|
+
|
|
|
|
{[allProObj[0].p_purity_real_show]} |
| Indirubin-3′-oxime |
|
✔
|
|
|
|
{[allProObj[0].p_purity_real_show]} |
| SU3327 |
+
|
+
|
+
|
+
|
|
{[allProObj[0].p_purity_real_show]} |
| JNK Inhibitor VIII |
|
++++
JNK1, Ki: 2 nM
JNK1, IC50: 45 nM
|
++++
JNK2, Ki: 4 nM
JNK2, IC50: 160 nM
|
+++
|
|
{[allProObj[0].p_purity_real_show]} |
| Doramapimod |
|
|
✔
|
|
|
{[allProObj[0].p_purity_real_show]} |
| RPI-1 |
|
|
✔
|
|
|
{[allProObj[0].p_purity_real_show]} |
| TCS JNK 5a |
|
|
++
|
++
|
|
{[allProObj[0].p_purity_real_show]} |
| SP 600125, negative control |
|
|
+
|
+
|
|
{[allProObj[0].p_purity_real_show]} |
|
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。
|
CEP-1347 临床研究
| NCT号 |
适应症或疾病 |
临床期 |
招募状态 |
预计完成时间 |
地点 |
|
NCT00404170
|
Parkinson Disease |
Phase 2 |
Completed |
- |
United States, Connecticut
... 展开 >>
Institute for Neurodegenerative Disorders
New Haven, Connecticut, United States, 06510 收起 << |
|
NCT00605163
|
- |
|
Unknown |
- |
- |
|
NCT00040404
|
Parkinson Disease |
Phase 2
Phase 3 |
Terminated(Unlikely to provide... 展开 >> evidence of significant effect) 收起 << |
- |
- |
CEP-1347 实验方案
| 计算器 |
|
| 存储液制备 |
 |
1mg |
5mg |
10mg |
|
1 mM
5 mM
10 mM
|
1.62mL
0.32mL
0.16mL
|
8.12mL
1.62mL
0.81mL
|
16.24mL
3.25mL
1.62mL
|
CEP-1347 技术信息
搜索
